Multisite research and clinical trials increasingly rely on a single IRB (sIRB) for review. This increase reflects federal mandates, sponsor expectations, and the operational realities of modern multisite or cooperative research. For institutions with a local
A strong protocol and well-drafted consent form are essential, but they are not enough on their own to support a
Let me start with a question I get more and more frequently from research sites as mRNA continues to expand
For sponsors, informed consent is one of the most visible signals of study quality during IRB review. It’s also a
Discover how AI and analytics are transforming clinical trial operations, from study startup to accrual workflows, in this insightful whitepaper.
A strong clinical trial protocol does more than describe how a study will run. It also helps reviewers understand why
Introducing the ‘Sponsor’s Guide to IRB Approval’ Institutional review board (IRB) approval protects the rights, safety, and welfare of research participants, and
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research.
In this webinar, leaders from cancer centers and biopharma companies will discuss the operational and institutional hurdles sites face and what can be done to address them. The panel will explore practical strategies to reduce burden, improve collaboration, and create a better experience for research staff and patients alike.
The release of ICH E6(R3) in January 2025 marks the most significant evolution in Good Clinical Practice (GCP) guidelines in over a decade. More than a revision, E6(R3) marks a shift from traditional practices—making participant safety and data reliability not just priorities, but design drivers, and introducing risk-based proportionality as a foundational approach.
Join experts from Johnson & Johnson Innovative Medicine, Bayer, The START Center for Cancer Care, and Advarra to discuss the ethical use of real-world data in clinical research.
Clinical research drives medical progress. Advarra ensures participant safety and ethical standards through expert IRB oversight for life-changing therapies.
